AMGN market-structure snapshot

$AMGN: multi-source stock research

Amgen Inc.

MARKET STRUCTURE

Latest close on August 12, 2026: $416.49 (+0.5% on the latest daily bar).

HMA21 / HMA55: $416.04 / $398.62. 200DMA: $348.14.

Relative volume: 0.34x the 20-day average.

Nearest support/watch zone: $409.00.

Nearest resistance/watch zone: $418.19.

Price is above the 200DMA, so the long-term trend reference is supportive.

FUNDAMENTALS AND VALUATION

Latest comparable filing period: 2026 Q2 ending 2026-06-30; filed 2026-08-05.

Comparable growth: revenue +9.5% YoY; net income +65.9% YoY; diluted EPS +64.9% YoY.

Quality and cash conversion: net margin 23.6% (+802 bp YoY); six-month YTD SEC free-cash-flow proxy $4.97B (+71.8% YoY).

Valuation snapshot: trailing P/E 25.8x; forward P/E 17.2x; EV/EBITDA 15.5x; P/S 5.9x.

Read-through:
• Net income grew faster than revenue, indicating positive earnings leverage in the comparable period.
• Cash generation improved versus the comparable period.

RECENT INSTITUTIONAL RESEARCH

• 2026-07-14 — Cardiovascular Drug Development Reaches a Key Milestone, with Catalysts in Two Major Areas Set to Shape the Sector’s Direction (Goldman Sachs)

Goldman Sachs’ global healthcare research shows two key cardiovascular catalysts in the third quarter following the failure of AZN/IONS’s CARDIO-TTRansform trial: NVS/IONS’s pelacarsen in the HORIZON trial and NVO’s ziltivekimab in the ZEUS study.

The results of these trials will test whether novel pharmacological mechanisms can translate into clinical benefit and could trigger significant share-price volatility for the companies involved. Investor expectations for HORIZON are currently low, implying potential upside if the results exceed expectations.

• 2026-07-14 — Lp(a) - Battle for the throne of new cardiovascular drugs: HORIZON trial results will determine the outcome (Goldman Sachs)

Goldman Sachs conducted an in-depth analysis of Lp(a), a genetic risk factor that affects approximately 1.4 billion people worldwide, independent of other factors. Development is currently entering a critical validation phase. Novartis/IONIS's HORIZON phase III trial is the first study to test whether lowering Lp(a) can bring cardiovascular benefits.

BOTTOM LINE

The technical structure is constructive, while the latest comparable period showed growth in both revenue and net income. The next confirmation must come from both price structure and the next reported operating data—not from narrative alone.

WHAT TO WATCH

• Holding above HMA21 near $416.04 would preserve the short-term structure.
• A close below the nearby support zone around $409.00 would weaken the setup.
• Whether the next filing confirms that revenue growth is converting into net income, EPS and cash flow.
• Whether the operating milestones identified in recent institutional research become measurable disclosures.

#Stocks #Fundamentals #TechnicalAnalysis #AMGN #NVO